Ondansetrom Labesfal (Ondansetron)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the central nervous system’s chemoreceptor trigger zone and on peripheral vagal afferents. This inhibition stops the neural signals that trigger the vomiting reflex, thereby reducing nausea and vomiting.

The dose of Ondansetrom Labesfal is determined by the prescribing clinician based on the specific indication, patient age, weight, and renal or hepatic function. Healthcare professionals adjust the regimen to achieve optimal antiemetic control while minimizing adverse effects.

Safety data for ondansetron in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which generally provides rapid and effective control of both acute and delayed nausea and vomiting. Compared with dopamine antagonists such as metoclopramide, ondansetron has a lower risk of extrapyramidal side effects and is often preferred for chemotherapy‑induced emesis.

Ondansetrom Labesfal should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing. Inspect the solution for particulate matter before use.

The product is supplied as an intravenous solution for injection. It is administered by a qualified healthcare professional via slow IV infusion or bolus, according to the prescribing information and the patient’s clinical condition.

Serious risks include QT interval prolongation, which can lead to potentially life‑threatening cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for these events, especially if they have pre‑existing cardiac conditions.

Ondansetrom Labesfal is contraindicated in individuals with known hypersensitivity to ondansetron or any component of the formulation. It should also be avoided in patients receiving apomorphine or those with a history of prolonged QT interval unless the benefits outweigh the risks.